← Back to Search

Checkpoint Inhibitor

Axitinib for Adenoid Cystic Carcinoma

Phase 2
Waitlist Available
Led By Renata Ferrarotto
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial studies the combo of axitinib & avelumab to see if it can better control adenoid cystic carcinoma than axitinib alone.

Eligible Conditions
  • Adenoid Cystic Carcinoma
  • Progressive Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate
Secondary outcome measures
Duration of response
Incidence of adverse events
Overall survival
+1 more

Side effects data

From 2019 Phase 2 trial • 13 Patients • NCT02129647
30%
Mucositis
10%
Fatigue
10%
Rash
10%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Axitinib

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (axitinib, avelumab)Experimental Treatment2 Interventions
Patients receive axitinib PO BID on days 1-28 and avelumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axitinib
FDA approved
Avelumab
FDA approved

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,766 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,631 Total Patients Enrolled
Renata FerrarottoPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
133 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are under observation in this medical study?

"That is accurate. The clinicaltrials.gov website says that the trial is currently recruiting patients. This study was posted on 7/22/2019, and it will last until 11/8/2022. They are looking for 30 participants between 1 site."

Answered by AI

To your knowledge, is this the initial experiment of this sort?

"Axitinib's journey through clinical trials began in 2011 with the first study being completed that same year. The initial trial, conducted by Pfizer, only involved 39 patients. Axitinib received its Phase 2 drug approval after this first study. As of now, there are 154 studies involving Axitinib underway across 1094 cities and 52 countries."

Answered by AI

What other scientific research studies have included Axitinib?

"Currently, there are 154 separate clinical trials investigating Axitinib. Out of those ongoing studies, 12 have reached Phase 3. The majority of these trials originate from Houston, Texas; however, 4333 medical centres worldwide are running Axitinib trials."

Answered by AI

For what reason is Axitinib generally prescribed?

"Axitinib is not only used to treat advanced thyroid cancer, but also aplastic anemia and merkel cell carcinoma."

Answered by AI

Are there any unfilled vacancies for volunteers in this experiment?

"The latest information from clinicaltrials.gov suggests that this study is looking for more participants. The trial was first posted on 7/22/2019 and the most recent update was on 11/8/2022."

Answered by AI

Are there any life-threatening risks associated with Axitinib?

"Axitinib has some clinical data supporting its safety, but none for efficacy. Our team scored it a 2."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
How old are they?
18 - 65
What site did they apply to?
M D Anderson Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
2019. "Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03990571.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top